

 Goodfellow Gems are chosen by Goodfellow Director, Bruce Arroll to be either practice changing or thought provoking. You are being mailed these as you are a member of the Goodfellow learning community.

Tacrolimus now funded for face eczema

Use of tacrolimus 0.1% and pimecrolimus 1% is for treatment of flares of moderate to severe atopic dermatitis and for maintenance and prevention in patients with a high frequency of atopic dermatitis exacerbations, i.e. 4 or more times per year.¹ They are particularly useful for the eyelids and face where skin atrophy is a risk. Neither product causes skin atrophy. They both need approval by a Dermatologist or Pediatrician.

Tacrolimus 0.1% is currently indicated for patients aged 16 and over while pimecrolimus 1% cream is indicated from age 3 months. However, off-label (OL) use of tacrolimus down to 3 months has been effective without significant side effects. OL use includes vitiligo in hair bearing areas. If no improvement after 8 weeks stop. Other OL use is psoriasis on the face.

Reference:

1. [Tacrolimus now funded for face eczema](#) Goodfellow MedCase (2023)

[Click here](#) to view more Gems



Tweet



Share



Forward

If this email was forwarded to you and you would like to automatically receive Goodfellow Gems [Click here](#).

Copyright © 2023 Goodfellow Unit, All rights reserved.

You are receiving this email as you have previously registered for a Goodfellow Unit event, or have opted in at our website www.goodfellowunit.org

Our mailing address is:

Goodfellow Unit
The University of Auckland | Grafton Campus
22-30 Park Ave, Grafton
Auckland, Auck 1023
New Zealand